Yes. In a study, RYBELSUS did not increase the risk of major cardiovascular (CV) events such as heart attack, stroke, or death. In a cardiovascular safety study, 3183 adults with type 2 diabetes and a high risk of CV events were treated once daily with either 14 mg RYBELSUS or a sugar pill in addition to their usual diabetes and CV medications.